Shares of Protagonist Therapeutics PTGX have gained nearly 7% over the past week. The upside came after the company announced ...
The name Harrison is mentioned in the conversation, but the male speaker is not Harrison; he remains unidentified. CSP Nwode and Inspector Harrison Akama were both associated with the Rapid Response ...
Johnson & Johnson’s Icotyde receives US FDA approval for first-line systemic treatment of plaque psoriasis with a targeted oral peptide: Spring House, Pennsylvania Friday, March ...
J&J wins FDA nod for Icotyde, a once-daily oral psoriasis pill, boosting its new drugs portfolio and challenging injectable treatments in a key market.
On February 10, 2026, the Saket Court issued a summons to Bina Modi and Lalit Bhasin in a case filed by her son Samir Modi. Delhi Police filed a charge sheet and said that there is no sufficient ...
ICOTYDE is the first and only IL-23R targeted oral peptide that delivers complete skin clearance and a favorable safety profile in a once-daily pill Approval supported by four phase 3 studies that met ...
Reps. Tom Gann, RInola, and Kevin West, RMoore, on Wednesday filed a brief asking the Oklahoma Supreme Court to overturn $98 million in rate increases for Oklahoma Natural Gas (ONG) well as $1.77 ...
Find all the best things to do in Pittsburgh this weekend, from NatureFest to the Pittsburgh Fringe Festival to the Japanese Film Festival.
Johnson & Johnson introduces the first and only IL-23R targeted oral peptide that delivers complete skin clearance and favorable safety profile in a once-daily pill ICOTYDE ...
Johnson & Johnson (JNJ) on Wednesday announced that the U.S. Food and Drug Administration (FDA) approved Icotyde, a once-daily pill developed with Protagonist Therapeutics (PTGX), as a treatment for ...
Pediatric patients with moderate to severe hidradenitits suppurativa may now receive secukinumab following new FDA approval for those aged 12 and up.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results